Cyproheptadine (Standard)
Cyproheptadine (Standard) is the analytical standard of Cyproheptadine (HY-B1622). This product is intended for research and analytical applications. Cyproheptadine acts as a p38 MAP kinase activator, CHK2 activator, histamine H1 receptor inhibitor and serotonin receptor inhibitor. Cyproheptadine mediates cell cycle arrest via G1 phase arrest, G1/S transition arrest, G0/G1 phase arrest, reduced expression of cyclins D1/D2/D3, upregulated expression of HBP1, p16, p21, p27, and decreased phosphorylation of retinoblastoma protein. Cyproheptadine induces Apoptosis by increasing PARP and cleaved PARP, as well as activating the mitochondrial caspase pathway. Cyproheptadine inhibits tumor growth with extremely low toxicity to normal cells. Cyproheptadine can be used in research related to hepatocellular carcinoma, multiple myeloma and acute myeloid leukemia.
For research use only. We do not sell to patients.
- CAS No.: 129-03-3
- Formula: C21H21N
- Molecular Weight:287.40
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 129-03-3
-
Molecular Weight 287.40
-
Formula C21H21N
-
SMILES
CN1CC/C(CC1)=C2C3=CC=CC=C3C=CC4=CC=CC=C/24
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Feng YM, et al. Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase. BMC Cancer. 2015;15:134. Published 2015 Mar 17. [Content Brief]
[2]. Mao X, et al. Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood. 2008;112(3):760-769. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Cyproheptadine (Standard) Related Classifications
HY-B1622R Related Classifications
Powered by Bioz
- Cyproheptadine (Standard)
- 129-03-3
- Reference Standards
- p38 MAPK
- Checkpoint Kinase (Chk)
- Histamine Receptor
- 5-HT Receptor
- CDK
- PARP
- Apoptosis
- CHK2
- histamine H1 receptor
- LP-1
- hepatocellular carcinoma
- acute myeloid leukemia
- human hematopoietic stem cells
- p38 MAP kinase
- serotonin receptor
- multiple myeloma
- MDAY-D2 cells
- Inhibitor
- inhibitor
- inhibit